Ymmunobio AG

Swiss Biotech Association

Member

Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. The proprietary CEACAM1 antibodies are having a direct co-stimulatory effect on immune cells in addition to interfering with the CEACAM1-CEACAM mediated check-point blockade.

Products, services, technology

Monoclonal Antibodies directed against CEACAM (Carcinoembryonic Antigen-related Cell Adhesion Molecules)

https://www.ymmunobio.com
‭+41 76 475 96 76‬
info@ymmuno.bio
Dr. Katrin Rupalla, CEO

Location

Gartengasse 12, 4125 Riehen, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2021
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

CELLnTEC Advanced Cell Systems

CELLnTEC technologies enable science and industry to develop innovations in stem cell research, regenerative medicine, cell-based therapies, and beyond. The company is a pioneering developer of chemically defined, animal and human components-free precision media.
3014 Bern

Member

Caland SA

Caland SA provides a professional, confidential, competitive and impeccable service of pharma-grade CO2 extraction, distillation and cannabis formulation based on GMP requirements.
A modern production line, coupled to a qualified ERP, ensures uncompromising quality of all products and services.
2800 Delémont

Member

Curare Swiss AG

Curare provides strategic advice to assist in the successful design of R&D programs. From the non-clinical to clinical Proof-of-Concept. The right decisions at the right time. Curare's experts put their years of experience and knowledge relating to translational and clinical drug development to use.
4056 Basel

Member